A Fully Magnetically Levitated Circulatory Pump for Advanced Heart Failure

In a randomized trial, 294 patients with advanced heart failure were assigned to receive either a new centrifugal-flow pump or an axial-flow pump. At 6 months, the centrifugal-flow pump was associated with better outcomes. A scarcity of effective therapeutic options for advanced heart failure has le...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:The New England journal of medicine Ročník 376; číslo 5; s. 440 - 450
Hlavní autoři: Mehra, Mandeep R, Naka, Yoshifumi, Uriel, Nir, Goldstein, Daniel J, Cleveland, Joseph C, Colombo, Paolo C, Walsh, Mary N, Milano, Carmelo A, Patel, Chetan B, Jorde, Ulrich P, Pagani, Francis D, Aaronson, Keith D, Dean, David A, McCants, Kelly, Itoh, Akinobu, Ewald, Gregory A, Horstmanshof, Douglas, Long, James W, Salerno, Christopher
Médium: Journal Article
Jazyk:angličtina
Vydáno: United States Massachusetts Medical Society 02.02.2017
Témata:
Adult
Aged
Aged, 80 and over
Clinical outcomes
Disease-Free Survival
Heart diseases
Heart failure
Heart Failure - mortality
Heart Failure - therapy
Heart-Assist Devices - adverse effects
Humans
Intention to Treat Analysis
Kaplan-Meier Estimate
Middle Aged
Motivation
Navigation behavior
Patients
Prosthesis Design
Prosthesis Failure
Quality of life
Stroke
Stroke - etiology
Surgeons
Survival
Thrombosis
Thrombosis - etiology
Transplantation
Transplants & implants
Ventricle
Young Adult
United States > US
ISSN:0028-4793, 1533-4406
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:In a randomized trial, 294 patients with advanced heart failure were assigned to receive either a new centrifugal-flow pump or an axial-flow pump. At 6 months, the centrifugal-flow pump was associated with better outcomes. A scarcity of effective therapeutic options for advanced heart failure has led to the development of durable mechanical circulatory support devices. Left ventricular assist devices, more accurately known as left ventricular assist systems, increase the rate of survival and improve quality of life among patients with advanced heart failure. However, these clinical benefits are balanced by an increased risk of infection, bleeding, neurologic events, and pump malfunction that is due principally to pump thrombosis. 1 , 2 As adoption of circulatory pumps has expanded, concerns about pump thrombosis have heightened. In 2013, two reports suggested that there has been an increase in . . .
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Article-2
ObjectType-Feature-1
content type line 23
ObjectType-Undefined-3
ISSN:0028-4793
1533-4406
DOI:10.1056/NEJMoa1610426